

Matthew J Taylor

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8796314/publications.pdf>

Version: 2024-02-01

36
papers

525
citations

759233

12
h-index

677142

22
g-index

40
all docs

40
docs citations

40
times ranked

946
citing authors

#	ARTICLE	IF	CITATIONS
1	A guide to cost-effective management of leg ulcers. British Journal of Health Care Management, 2021, 27, 136-144.	0.2	0
2	<p><Standard Gamble to Derive Utility Health States for Limbal Stem Cell Deficiency</p><p>ClinicoEconomics and Outcomes Research, 2020, Volume 12, 535-546.	1.9	5
3	How health inequalities accumulate and combine to affect treatment value: A distributional cost-effectiveness analysis of smoking cessation interventions. Social Science and Medicine, 2020, 265, 113339.	3.8	5
4	Evaluating the cost-effectiveness of combination inhalers for the management of chronic obstructive pulmonary disease. British Journal of Health Care Management, 2020, 26, 231-233.	0.2	0
5	NICE, in Confidence: An Assessment of Redaction to Obscure Confidential Information in Single Technology Appraisals by the National Institute for Health and Care Excellence. Pharmacoeconomics, 2019, 37, 1383-1390.	3.3	11
6	<p><The impact of increased post-progression survival on the cost-effectiveness of interventions in oncology</p><p>ClinicoEconomics and Outcomes Research, 2019, Volume 11, 309-324.	1.9	3
7	A national economic and clinical model for ischemic stroke care development in Saudi Arabia: A call for change. International Journal of Stroke, 2019, 14, 835-842.	5.9	13
8	Evaluating the effectiveness and cost-effectiveness of the Smoking Treatment Optimisation in Pharmacies (STOP) intervention: protocol for a cluster randomised controlled trial. Trials, 2019, 20, 337.	1.6	4
9	Cost-Effectiveness of Docetaxel and Paclitaxel for Adjuvant Treatment of Early Breast Cancer: Adaptation of a Model-Based Economic Evaluation From the United Kingdom to South Africa. Value in Health Regional Issues, 2019, 19, 65-74.	1.2	11
10	Recent Developments in Health Economic Modelling of Cancer Therapies. Recent Results in Cancer Research, 2019, 213, 143-151.	1.8	1
11	Cost-effectiveness of sacubitril/valsartan in the treatment of heart failure with reduced ejection fraction. Heart, 2018, 104, 1006-1013.	2.9	50
12	Modelling the cost-effectiveness of tofacitinib for the treatment of rheumatoid arthritis in the United States. Current Medical Research and Opinion, 2018, 34, 1991-2000.	1.9	13
13	The Future of Precision Medicine: Potential Impacts for Health Technology Assessment. Pharmacoeconomics, 2018, 36, 1439-1451.	3.3	84
14	An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis After Methotrexate or After 1 or 2 TNF Inhibitors from a U.S. Payer Perspective. Journal of Managed Care & Specialty Pharmacy, 2018, 24, 1010-1017.	0.9	14
15	Smoking Cessation: A Comparison of Two Model Structures. Pharmacoeconomics, 2018, 36, 1101-1112.	3.3	10
16	The role of health economics in the evaluation of surgery and operative technologies. Surgery, 2017, 161, 300-304.	1.9	4
17	Comparing Increments in Utility of Health: An Individual-based Approach. Value in Health, 2017, 20, 224-229.	0.3	9
18	Cost-utility analysis of the insufflation of warmed humidified carbon dioxide during open and laparoscopic colorectal surgery. Expert Review of Pharmacoeconomics and Outcomes Research, 2017, 17, 99-107.	1.4	4

#	ARTICLE	IF	CITATIONS
19	Challenges Associated with Estimating Utility in Wet Age-Related Macular Degeneration: A Novel Regression Analysis to Capture the Bilateral Nature of the Disease. <i>Advances in Therapy</i> , 2017, 34, 2360-2370.	2.9	6
20	Simulation Modelling in Ophthalmology: Application to Cost Effectiveness of Ranibizumab and Aflibercept for the Treatment of Wet Age-Related Macular Degeneration in the United Kingdom. <i>Pharmacoeconomics</i> , 2017, 35, 237-248.	3.3	17
21	Understanding the relationship between costs and the modified Rankin Scale: A systematic review, multidisciplinary consensus and recommendations for future studies. <i>European Stroke Journal</i> , 2017, 2, 3-12.	5.5	21
22	Cost-effectiveness of SQ® HDM SLIT-tablet in addition to pharmacotherapy for the treatment of house dust mite allergic rhinitis in Germany. <i>ClinicoEconomics and Outcomes Research</i> , 2017, Volume 9, 77-84.	1.9	7
23	An Economic Evaluation of Tofacitinib Treatment in Rheumatoid Arthritis: Modeling the Cost of Treatment Strategies in the United States. <i>Journal of Managed Care & Specialty Pharmacy</i> , 2016, 22, 1088-1102.	0.9	24
24	Cost-Effectiveness Analysis of d-Nav for People with Diabetes at High Risk of Neuropathic Foot Ulcers. <i>Diabetes Therapy</i> , 2016, 7, 511-525.	2.5	9
25	The Cost-Effectiveness of Ranibizumab Treat and Extend Regimen Versus Aflibercept in the UK. <i>Advances in Therapy</i> , 2016, 33, 1660-1676.	2.9	14
26	A Differential Item Functioning Analysis of the EQ-5D in Cancer. <i>Value in Health</i> , 2016, 19, 1063-1067.	0.3	10
27	A United Kingdom-based economic evaluation of ranibizumab for patients with retinal vein occlusion (RVO). <i>Journal of Medical Economics</i> , 2014, 17, 423-434.	2.1	10
28	Most domains of the European Organisation for Research and Treatment of Cancer Quality of Life Questionnaire C30 are reliable. <i>Journal of Clinical Epidemiology</i> , 2014, 67, 952-957.	5.0	14
29	P2-247: THE SENSITIVITY AND SPECIFICITY OF COMPUTERISED OR PAPER-AND-PENCIL COGNITIVE ASSESSMENTS USED IN PRIMARY CARE IMPACT THE COST-EFFECTIVENESS OF THE DEMENTIA DIAGNOSTIC PATHWAY. , 2014, 10, P566-P566.		0
30	Cost effectiveness of interventions to reduce relapse to smoking following smoking cessation. <i>Addiction</i> , 2011, 106, 1819-1826.	3.3	25
31	Evaluation of treatment options for fractured tibia. <i>British Journal of Health Care Management</i> , 2009, 15, 430-439.	0.2	1
32	Pharmacoeconomic benefits of dasatinib in the treatment of imatinib-resistant patients with chronic myelogenous leukemia. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2009, 9, 117-121.	1.4	5
33	An Economic Evaluation of Valsartan for Post-MI Patients in the UK Who Are Not Suitable for Treatment with ACE Inhibitors. <i>Value in Health</i> , 2009, 12, 459-465.	0.3	13
34	An Economic Evaluation of Dasatinib for the Treatment of Imatinib-Resistant Patients with Chronic Myelogenous Leukaemia.. <i>Blood</i> , 2009, 114, 4535-4535.	1.4	2
35	An economic evaluation of sevelamer in patients new to dialysis. <i>Current Medical Research and Opinion</i> , 2008, 24, 601-608.	1.9	28
36	Acute coronary syndromes in Europe: 1-year costs and outcomes. <i>Current Medical Research and Opinion</i> , 2007, 23, 495-503.	1.9	76